37
Participants
Start Date
January 5, 2021
Primary Completion Date
April 24, 2025
Study Completion Date
April 24, 2025
Trabectedin 1 MG [Yondelis]
Patients with Ewing sarcoma will be administered trabectedin intravenously. Cycles are 21 days.
Irinotecan
Patients with Ewing sarcoma will be administered inirotecan intravenously. Cycles are 21 days.
tumor biopsy
Tumor tissue samples will be collected collected at two timepoints. The first biopsy will be prior to treatment. If a biopsy is not possible archival tissue may be submitted. A second tumor biopsy will be taken fro consenting patients when possible after the first administration of Trabectedin to evaluate the effect on the tumor cells.
3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging
Some patients will receive PET scans with the use of 18F-FLT, a radioactive tracer, performed at the National Institute of Health.
Children's Hospital of Philadelphia, Philadelphia
University of Pennsylvania, Philadelphia
National Cancer Institute, Bethesda
University of Michigan, Ann Arbor
Children's Hospital of Los Angeles, Los Angeles
Boston Children's Hospital / Dana Farber Cancer Institute, Boston
Janssen Scientific Affairs, LLC
INDUSTRY
National Institutes of Health (NIH)
NIH
National Cancer Institute (NCI)
NIH
Sarcoma Alliance for Research through Collaboration
OTHER